
Dupixent: An injected biologic for moderate to severe eczema. It blocks two of the immune signals that drive the itch, and it is taken long term rather than as a course. Vtama: A once-daily steroid-free cream for plaque psoriasis. It can be used anywhere on the body, including the face and skin folds, and some people stay clear for months after stopping.


Choose for moderate to severe eczema that creams can't control, as a long-term treatment without blood tests.
Choose for psoriasis or eczema anywhere on the body when you want a once-daily non-steroid with no time limit.
Can you take them together?
Vtama can be used on remaining eczema patches while on Dupixent. They do not interact.
Compare uses by strength of evidence. Evidence level describes confidence in a benefit, not its size.










Blocks IL-4 and IL-13 signals: Binds their shared receptor to interrupt these messages. Calms type 2 inflammation: Reduces immune signaling that drives eczema. Eases eczema and itch: Inflamed skin and itch improve as signaling falls.
Dupilumab binds IL-4 receptor alpha, inhibiting IL-4 and IL-13 signaling. Diagram focuses on atopic dermatitis; it does not show every approved indication or all downstream effects.

Activates AhR: Binds a receptor that helps regulate skin-cell behavior. May rebalance inflammation: Changes in immune signaling may help calm skin. May support the skin barrier: Changes in barrier proteins may help skin function.
Tapinarof is an AhR agonist; the specific therapeutic mechanisms are unknown. Anti-inflammatory and barrier effects are proposed from experimental evidence and are explicitly qualified.
There is no titration. The number is fixed by age and weight; the only variable is how often you inject.
Loading dose: Adults start with two 300 mg injections the same day at two different spots — 600 mg total. That front-loading reaches a working level quickly.
Usual dose: 300 mg every two weeks for adults. Adolescents 12 and over who weigh about 60 kg or more use the same schedule.
Children and smaller adolescents: Dose is set by weight, and the youngest children inject every four weeks rather than every two. Go by the prescription.
Going up: There is nothing higher. If it is not working at sixteen weeks, the conversation is about a different treatment, not a bigger dose.
Total course: Open-ended. This is maintenance, not a course — people stay on it for years when it works.
When to Apply: Once a day, at whatever time you will remember. A thin layer over the plaques, rubbed in. It can go on the face, eyelids, armpits, groin and under the breasts, which sets it apart from a steroid. Wash your hands afterwards unless your hands are being treated.
How to Start: Once daily from day one, on every plaque you want treated. No ramp-up, and no cap on how much of the body can be covered, so it does not have to be rationed the way a strong steroid does.
If It Irritates: Small red bumps around hair follicles are the most common problem and usually appear in the first few weeks. Most are not infection and often settle without stopping. Stinging or a rash where you applied it is the other pattern, and that one is worth showing your doctor, because a true contact allergy means stopping.
If It’s Not Working: There is one strength, so there is nothing to increase. Give it a full twelve weeks. If plaques are still thick then, the conversation is about adding something else, phototherapy, or moving to a tablet or injection.
Pick a day of the week and keep it. Take the pen or syringe out of the fridge 30 to 45 minutes ahead and let it warm to room temperature on its own — never in hot water, on a radiator, or in a microwave. A cold injection stings much more, and that one step explains most of the difference between people.
Inject into the front of the thigh or the abdomen, at least two inches from the navel. The upper arm works if someone else is injecting. Change the spot each time and avoid skin that is bruised, tender, scarred, or flaring. If the dose is two injections, give them one after the other in two different spots.
Give it as soon as you remember, as long as that is within about a week of the due day, then go back to your schedule. If longer than that, skip it and take the next on the usual day. Never double up to catch up. One missed injection does not undo months of treatment.
No routine blood tests are required — no liver, kidney, or blood count checks, which is a real advantage over the older systemic eczema drugs. Monitoring is a conversation about the skin, the itch, and the eyes.
Ask about the eyes at every visit. Conjunctivitis affects roughly one in ten people treated for eczema, more often with severe skin or eyelid involvement, and usually responds to lubricating drops or a short prescription course. Eye pain or changed vision goes to an eye doctor rather than being watched. Eosinophil counts rise in some people without causing anything, so a count taken for another reason should be read with that in mind.
Nothing builds up over the years, and there is no ceiling on how long you can stay on it. The recurring problem is insurance renewal, not safety.
No blood tests are required. There is nothing to check on a lab report, which is one of the practical arguments for a topical over a tablet.
Monitoring is a look at the skin and a conversation, usually at about twelve weeks. Two things get asked about: folliculitis, and whether it is a few bumps or enough to be a problem; and whether the treated skin has become itchy and inflamed in a new way, which points to contact dermatitis rather than psoriasis.
Long term there is no organ risk to track and no skin thinning to watch for, so there is no maximum duration. What is genuinely not known yet is what many years of continuous use looks like, because the drug is recent. A common pattern is to treat until clear, stop, and restart when plaques come back.
Approximate windows, not promises.
First few minutesThe injection: A sting for a few seconds, then redness or aching. Common early, and it settles with later doses.
First few minutesApplying it: A thin layer once a day on the plaques.
Weeks 1 to 2Itch lifts: Often within days, before anything shows in the mirror. The earliest and most reliable change.
Weeks 2 to 8Working: Sleep improves, scratching drops, and the skin looks calmer. Red or gritty eyes, if they happen, start here.
Weeks 12 to 16Judge it here: Trials measured their main result at sixteen weeks. Most responders reach their best skin here and a good number get close to clear; people only partly better at twelve often kept improving.
Weeks 12 to 24Sleep and daily life: These follow the itch, on a similar timeline, and trials measured them separately from the rash.
After 6 monthsThe face and neck: A stubborn pink patch appears here in a minority, usually after the rest of the skin has cleared. It is treatable and not a sign the drug has stopped working.
Weeks 1 to 4Starting: Scale and roughness ease before the redness does, often by week four. Folliculitis shows up now if it is going to, usually small tender bumps in hair-bearing areas.
Weeks 4 to 8Working: Plaques flatten and shrink, and color fades from red toward pink or brown.
Weeks 8 to 12Judge it here: Trials measured their main result at twelve weeks, and many people were still improving then. A meaningful minority reached clear or almost clear skin — a realistic target, not a promise.
After stoppingRemission: Unlike a steroid, it does not usually rebound. People who cleared completely often stayed clear for months before restarting.
Sorted by what to do about them.
Cost decides access here more often than anything medical. Dupilumab is a biologic with no generic and no biosimilar in the United States, and the list price runs to tens of thousands of dollars a year. Almost nobody pays that, and almost everybody has to do the paperwork that brings it down.
Prior authorization is close to universal. Plans want a diagnosis, a record of how much of the body is affected, and evidence that prescription topicals were tried and could not hold the disease — usually a mid- or high-strength steroid, often a calcineurin inhibitor too. Some add phototherapy or an older systemic drug first. First-pass denials are common and appeals often succeed, so a denial is a step, not the end. Ask the prescribing office who handles appeals.
The manufacturer's copay program cuts the monthly cost sharply for people with commercial insurance, and a separate program covers people with no insurance. Copay cards cannot be used with Medicare, Medicaid, or other government plans, which is where the largest out-of-pocket gaps sit. Terms change every year, so a plan that refused last year is worth asking again.
Brand only, with no generic. It is one of the more expensive topicals for psoriasis and costs far more than a generic steroid or generic calcipotriene.
Coverage varies and prior authorization is common; plans frequently want to see a topical steroid, and often a vitamin D analog, tried first. Manufacturer copay cards exist and the terms change, so check the current one.
Because a tube covers only so much, cost climbs quickly with widespread psoriasis, which is one of the main reasons people end up on a tablet or injection instead.
Itch often improves within two weeks. The skin takes longer — sixteen weeks is the fair point to judge.
It stings for a few seconds. Letting it reach room temperature first makes the biggest difference.
Roughly one in ten get red or gritty eyes, more often with severe eczema or eyelid involvement. Most settle with drops.
No routine tests, which is unusual for a drug of this kind.
Some people do, and some keep a good stretch. Eczema usually returns eventually, and restarting normally works.
Yes. Most people need far less, but flares still get topical treatment, and moisturizer continues indefinitely.
No. It works on a different switch inside the skin cell, the aryl hydrocarbon receptor. That is why there is no time limit and no skin thinning.
Yes — approved for the face and skin folds, one of its main advantages over a steroid.
Most likely folliculitis — small red bumps around hair follicles where you applied it. The most common side effect in the trials, at roughly one in five people, usually mild, and most carried on.
Give it twelve weeks. Some change usually shows by four.
That is a normal way to use it. In the long-term study, many who cleared completely stayed clear for months, then restarted when plaques returned.
Yes, it is also approved for atopic dermatitis, in adults and in children from age two.